These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8991107)

  • 1. [Presence of ophthalmopathy in all cases of Basedow disease?].
    Duprey J; Moisson-Meer A; Sultan M; Ducornet B; Lifchitz E
    Ann Endocrinol (Paris); 1996; 57(5):429-32. PubMed ID: 8991107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.
    Baschieri L; Antonelli A; Nardi S; Alberti B; Lepri A; Canapicchi R; Fallahi P
    Thyroid; 1997 Aug; 7(4):579-85. PubMed ID: 9292946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of ophthalmopathy in Basedow disease. Follow-up of patients one year following diagnosis of hyperthyroidism].
    Vangheluwe O; Ducasse A; Vaudrey C; Maes B; Delisle MJ
    J Fr Ophtalmol; 1994; 17(5):331-8. PubMed ID: 8089419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' ophthalmopathy--a clinical review.
    Carter JN
    Aust N Z J Ophthalmol; 1990 Aug; 18(3):239-42. PubMed ID: 2261168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence of eye diseases in Basedow disease. Apropos of a prospective study with 85 cases].
    Vangheluwe O; Ducasse A; Vaudrey C; Maes B; Delisle MJ; Segal A
    J Fr Ophtalmol; 1992; 15(8-9):469-73. PubMed ID: 1294610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.
    Leövey A; Bakó G; Szabó J; Kálmán K; Fórizs E
    Acta Med Hung; 1992-1993; 49(3-4):179-85. PubMed ID: 1345455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of Graves' ophthalmopathy.
    Feldon S
    Thyroid; 1993; 3(2):171. PubMed ID: 8369655
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay.
    Ahmann A; Baker JR; Weetman AP; Wartofsky L; Nutman TB; Burman KD
    J Clin Endocrinol Metab; 1987 Mar; 64(3):454-60. PubMed ID: 2434519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
    Yang H; Wu Z; Huang X; Xie C; Yang P
    Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy: current concepts regarding pathogenesis and management.
    Burch HB; Wartofsky L
    Endocr Rev; 1993 Dec; 14(6):747-93. PubMed ID: 8119236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of urinary mucopolysaccharides in Graves' disease.
    Ursu H; Dumitrescu C; Bartoc R; Dumitriu L
    Endocrinologie; 1984; 22(4):277-82. PubMed ID: 6240765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dysthyroid optic neuropathy. Apropos of 2 cases].
    Domenjôd M; Merle H; Gerard M; Ayeboua L; Poman G
    J Fr Ophtalmol; 1996; 19(8-9):543-50. PubMed ID: 8944137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress.
    Heufelder AE
    Eur J Endocrinol; 1995 May; 132(5):532-41. PubMed ID: 7749490
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
    Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
    N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postural variation of exophthalmometry in Graves' ophthalmopathy.
    Asad R; Tewari HK; Ahuja MM; Mithal A
    Indian J Ophthalmol; 1990; 38(4):166-8. PubMed ID: 2086467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.